Aeterna Zentaris Inc. announced that the European Medicines Agency has granted marketing authorization for macimorelin, an orally available ghrelin agonist, for diagnosis of adult growth hormone deficiency. The approval came following the Committee for Medicinal Products for Human Use positive opinion of macimorelin on November 15, 2018. Adult growth hormone deficiencymay occur in an adult subject who has a history of childhood onset growth hormone deficiency or may occur during adulthood as an acquired condition. Considering a population of 510 million for the European Community, research based on incidence prevalence suggests that at least 35,000 adults could be afflicted with growth hormone deficiency.